

EQA round: CSFB1/25 - Cerebrospinal Fluid Analysis

Deadline: 7.2.2025

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
(333) Albumin	[mg/L]				75							75	73	97	
Sample A		239	19	7,8	75		CVP	239	5,3	23%	184	294	75	73	97
(1) Abbott		254	7,4	2,9	7	0							7		
(58) Beckman Coulter (AU)		238	8,7	3,6	10	0							10		
(60) Roche		236	9,4	4	23	0							23		
(149) Siemens (Dade, BN, Dimension)		255	27	11	10	0							10		
(162) Siemens (Atellica)		217	32	15	13	0							13		
(179) Siemens		237	27	11	6	0							6		
Other					6	0							6		
								3x 12, 2x 91, 1x 152							
Sample B		349	26	7,5	75		CVP	349	7,4	23%	268	430	75	74	99
(1) Abbott		370	16	4,4	7	0							7		
(58) Beckman Coulter (AU)		353	13	3,7	10	0							10		
(60) Roche		342	13	3,8	23	0							23		
(149) Siemens (Dade, BN, Dimension)		367	40	11	10	0							10		
(162) Siemens (Atellica)		319	50	16	13	0							13		
(179) Siemens		345	37	11	6	0							6		
Other					6	0							6		
								3x 12, 2x 91, 1x 152							
(330) Total protein	[mg/L]				97							97	96	99	
Sample A		407	26	6,3	97		CVP	407	6,4	27%	297	517	97	96	99
(1) Abbott		380	26	6,8	11	0							11		
(58) Beckman Coulter (AU)		409	12	2,9	15	0							15		
(60) Roche		397	15	3,8	41	0							41		
(162) Siemens (Atellica)		450	15	3,4	16	0							16		
Other					14	0							14		
								2x 46, 1x 75, 3x 77, 1x 85, 1x 158, 1x 166, 1x 178, 3x 179, 1x 998							
Sample B		1030	43	4,2	97		CVP	1030	11	27%	751	1310	97	97	100
(1) Abbott		968	77	7,9	11	0							11		
(58) Beckman Coulter (AU)		1070	36	3,3	15	0							15		
(60) Roche		1040	22	2,2	41	0							41		
(162) Siemens (Atellica)		1000	17	1,7	16	0							16		
Other					14	0							14		
								2x 46, 1x 75, 3x 77, 1x 85, 1x 158, 1x 166, 1x 178, 3x 179, 1x 998							
(331) Glucose	[mmol/L]				97							97	97	100	
Sample A		3,28	0,095	2,9	97		CVP	3,28	0,024	18%	2,68	3,88	97	97	100
(1) Abbott		3,26	0,089	2,7	9	0							9		
(58) Beckman Coulter (AU)		3,24	0,094	2,9	17	0							17		
(60) Roche		3,27	0,066	2	41	0							41		
(162) Siemens (Atellica)		3,33	0,097	2,9	17	0							17		
Other					13	0							13		
								4x 46, 1x 75, 2x 158, 1x 178, 3x 179, 1x 187, 1x 188							
Sample B		1,7	0,039	2,3	97		CVP	1,7	0,01	18%	1,39	2,01	97	97	100
(1) Abbott		1,68	0,037	2,2	9	0							9		
(58) Beckman Coulter (AU)		1,68	0,051	3	17	0							17		
(60) Roche		1,69	0,022	1,3	41	0							41		
(162) Siemens (Atellica)		1,74	0,052	3	17	0							17		
Other					13	0							13		
								4x 46, 1x 75, 2x 158, 1x 178, 3x 179, 1x 187, 1x 188							
(335) IgA	[mg/L]				22							22	17	77	
Sample A		10	0,76	7,6	22		CVP	10	0,4	32%	6,8	13,2	22	21	95
(149) Siemens (Dade, BN, Dimension)		9,72	0,41	4,2	9	0							9		
(162) Siemens (Atellica)		9,73	0,56	5,7	5	0							5		
Other					8	0							8		
								3x 12, 3x 91, 2x 179							
Sample B		37	9,7	26	22		CVP	37	5,1	32%	25,1	48,9	22	17	77
(149) Siemens (Dade, BN, Dimension)		31,6	5,3	17	9	0							9		
(162) Siemens (Atellica)		33,4	4,2	12	5	0							5		
Other					8	0							8		
								3x 12, 3x 91, 2x 179							
(334) IgG	[mg/L]				44							44	42	95	
Sample A		59,3	3,2	5,4	44		CVP	59,3	1,2	24%	45	73,6	44	42	95
(60) Roche		57,5	3,4	5,9	14	0							14		
(91) Binding Site		61,2	1,9	3	6	0							6		

EQA round: CSFB1/25 - Cerebrospinal Fluid Analysis

Deadline: 7.2.2025

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL				
(149) Siemens (Dade, BN, Dimension)		60,6	3,3	5,5	11	0							11		
(162) Siemens (Atellica)		60	2,3	3,8	5	0							5		
Other					8	1							8		
							3x 12, 1x 29, 1x 58, 3x 179								
Sample B		460	23	4,9	44		CVP	460	8,4	24%	349	571	44	43	98
(60) Roche		451	16	3,6	14	0							14		
(91) Binding Site		487	18	3,8	6	0							6		
(149) Siemens (Dade, BN, Dimension)		463	22	4,7	11	0							11		
(162) Siemens (Atellica)		457	23	5	5	0							5		
Other					8	1							8		
							3x 12, 1x 29, 1x 58, 3x 179								
(336) IgM	[mg/L]				30								30	26	87
Sample A		4,07	0,37	9	30		CVP	4,07	0,17	31%	2,8	5,34	30	29	97
(91) Binding Site		3,94	0,29	7,3	5	0							5		
(149) Siemens (Dade, BN, Dimension)		4,05	0,35	8,7	11	0							11		
Other					14	1							14		
							3x 12, 1x 29, 4x 60, 4x 162, 2x 179								
Sample B		15,5	1,6	10	30		CVP	15,5	0,71	31%	10,6	20,4	30	26	87
(91) Binding Site		14,6	0,86	5,9	5	0							5		
(149) Siemens (Dade, BN, Dimension)		15,1	0,64	4,2	11	0							11		
Other					14	1							14		
							3x 12, 1x 29, 4x 60, 4x 162, 2x 179								
(338) Lactate	[mmol/L]				95								95	94	99
Sample A		1,92	0,063	3,3	95		CVP	1,92	0,016	20%	1,53	2,31	95	95	100
(1) Abbott		2,01	0,015	0,74	7	0							7		
(58) Beckman Coulter (AU)		1,88	0,042	2,3	17	0							17		
(60) Roche		1,93	0,038	1,9	43	0							43		
(162) Siemens (Atellica)		1,95	0,046	2,4	17	0							17		
Other					11	0							11		
							1x 61, 2x 75, 2x 116, 1x 178, 3x 179, 2x 188								
Sample B		3,86	0,1	2,7	95		CVP	3,86	0,026	20%	3,08	4,64	95	94	99
(1) Abbott		3,94	0,21	5,3	7	0							7		
(58) Beckman Coulter (AU)		3,83	0,093	2,4	17	0							17		
(60) Roche		3,86	0,077	2	43	0							43		
(162) Siemens (Atellica)		3,87	0,088	2,3	17	0							17		
Other					11	0							11		
							1x 61, 2x 75, 2x 116, 1x 178, 3x 179, 2x 188								